Vanguard Group
GRCE

Vanguard Group’s Grace Therapeutics GRCE Stock Holding History

Vanguard Group’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.48M Buy
423,981
+14,881
+4% +$47.3K ﹤0.01% 3656
2025
Q3 		$1.22M Hold
409,100
– – ﹤0.01% 3733
2025
Q2 		$1.22M Buy
409,100
+153,700
+60% +$409K ﹤0.01% 3691
2025
Q1 		$582K Buy
255,400
+30,400
+14% +$95.8K ﹤0.01% 3848
2024
Q4 		$857K Buy
+225,000
New +$770K ﹤0.01% 3811

Other funds holding GRCE

NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Vanguard Group's GRCE Position: Q4 2025 in Review

Vanguard Group increased its Grace Therapeutics (GRCE) stake by 3.6% in Q4 2025, buying an estimated $47.3K and bringing the position to 423,981 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #3656.

Vanguard Group first reported a position in GRCE in Q4 2024 and has held it in 5 quarters since. 23 funds tracked by Wall St. Rank hold GRCE as of Q4 2025.

  • Vanguard Group held 423,981 shares of Grace Therapeutics worth $1.48M as of Q4 2025.
  • Vanguard Group bought 14,881 Grace Therapeutics shares in Q4 2025, an estimated $47.3K.
  • Grace Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3656 holding.
  • Vanguard Group first reported a position in Grace Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • 23 funds tracked by Wall St. Rank held Grace Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.